

Patient REPORT, SAMPLE	Requesting Physician	Accession Number 12345678
Date of Birth 04/15/1983	Sex M	Report to QUEST DIAGNOSTICS
Specimen Type Serum	Address 200 FOREST STREET	Family Number/Kindred Number
Test Category Diagnostic (Symptomatic)	2ND FLOOR	Patient Number 00000000
Test Requested NAbFeron (IFN-b) Antibody Test	MARLBOROUGH, MA 01752	Specimen Collection Date 11/08/2019
	Additional Reports to:	Date Received 11/10/2019
		Report Date 11/15/2019

NAbFeron (IFN-b) Antibody Test

This analysis detected a highly elevated level of neutralizing antibodies (NAbs) to human interferon (IFN) beta.

INTERPRETIVE RESULTS TABLE			
	Test	Technical Result	Reference Range
Elevated	NAbs to IFN beta	>1:640	not elevated <1:20, mild/moderately elevated 1:20-1:100, highly elevated >1:100

Recommendations: Health care providers, please contact the Athena Diagnostics Client Services Department at 1-800-394-4493 if you wish to speak with a clinical consultant regarding this test result.

Background information: The presence of neutralizing antibodies to interferon beta, especially in persistently high titers, may be associated with a reduction in the clinical effectiveness of interferon beta therapy (1). Although the measurement of NAbs can add to the clinical and imaging information used to assess the efficacy of interferon beta therapy, these results should be interpreted in the context of clinical presentation and medical history (2, 3).

Methods:

Detection of antibodies was performed using a viral cytopathic effect bioassay.

Limitations of analysis: Although rare, false positive or false negative results may occur. All results should be interpreted in the context of clinical findings, relevant history, and other laboratory data.

Background References

- Goodin, DS, et al. (2007) Neurology 68:977-984 (PMID:17389300)
- Polman, CH, et al. (2010) Lancet Neurol 9:740-50 (PMID:20610349)
- Creeke, PI, et al. (2013) Ther Adv Neurol Disord 6:3-17 (PMID:23277789)

This test was developed and its analytical performance characteristics have been determined by Athena Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

Laboratory oversight provided by Vivekananda Datta, M.D., Ph.D., CLIA license holder, Athena Diagnostics (CLIA# 22D0069726)